Zacks: Brokerages Anticipate Menlo Therapeutics (MNLO) to Post -$0.68 EPS

Wall Street brokerages expect Menlo Therapeutics (NASDAQ:MNLO) to announce earnings per share of ($0.68) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Menlo Therapeutics’ earnings. The highest EPS estimate is ($0.65) and the lowest is ($0.71). The firm is scheduled to report its next earnings results on Wednesday, June 27th.

On average, analysts expect that Menlo Therapeutics will report full year earnings of ($3.20) per share for the current financial year, with EPS estimates ranging from ($3.34) to ($3.05). For the next year, analysts expect that the business will post earnings of ($3.63) per share, with EPS estimates ranging from ($4.11) to ($3.14). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Menlo Therapeutics.

How to Become a New Pot Stock Millionaire

Menlo Therapeutics (NASDAQ:MNLO) last posted its quarterly earnings data on Wednesday, March 28th. The company reported ($1.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($1.11). The company had revenue of $2.78 million during the quarter.

A number of research firms recently issued reports on MNLO. Jefferies Group cut Menlo Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, April 9th. JMP Securities began coverage on Menlo Therapeutics in a report on Tuesday, February 20th. They set an “outperform” rating and a $44.00 price objective for the company. Piper Jaffray began coverage on Menlo Therapeutics in a report on Tuesday, February 20th. They set an “overweight” rating and a $48.00 price objective for the company. Finally, Guggenheim began coverage on Menlo Therapeutics in a report on Monday, February 19th. They set a “buy” rating and a $52.00 price objective for the company.

In other news, major shareholder Vivo Capital Surplus Fund Viii bought 294,118 shares of the stock in a transaction on Thursday, January 25th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $5,000,006.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

MNLO traded up $0.02 during trading hours on Thursday, reaching $9.53. 47,581 shares of the company’s stock traded hands, compared to its average volume of 237,182. Menlo Therapeutics has a 52-week low of $7.94 and a 52-week high of $39.86.

WARNING: “Zacks: Brokerages Anticipate Menlo Therapeutics (MNLO) to Post -$0.68 EPS” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://sportsperspectives.com/2018/04/17/zacks-brokerages-anticipate-menlo-therapeutics-mnlo-to-post-0-68-eps.html.

About Menlo Therapeutics

Menlo Therapeutics Inc, a biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis.

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply